Novel Perspectives for Glutamatergic Strategies, Psychedelics and Antipsychotic Augmentation in Treatment Resistant Depression: A Narrative Review

Abstract

Introduction: Treatment-Resistant Depression (TRD) affects approximately 30-50% of patients with Major Depressive Disorder (MDD) who fail to respond to at least two adequate antidepressant trials. This condition presents substantial clinical and functional challenges, and no universally accepted treatment algorithm currently exists. Emerging therapeutic strategies, particularly glutamatergic modulators and psychedelics, have shown promising results in managing TRD. Methods: We conducted a narrative review using PubMed and Scopus with the query “(treatment resistant depression OR TRD) AND (glutamatergic OR glutamate OR psychedelic OR psilocybin OR antipsychotic augmentation) NOT (review OR animal OR mouse).” After applying inclusion/exclusion criteria, 60 articles were selected. Results: The most frequently studied treatments (43 studies) are glutamatergic agents, particularly intravenous ketamine and intranasal esketamine, which have consistently demonstrated rapid and clinically meaningful reductions in depressive symptoms. Augmentation with atypical antipsychotics also showed effectiveness for partial responders. Psychedelic-assisted therapies yielded sustained antidepressant benefits and modulated biomarkers such as BDNF and inflammatory markers. Discussion and Conclusion: The findings support a potential paradigm shift away from traditional monoaminergic-based treatments toward more personalized, mechanism-driven strategies for managing TRD. Ketamine and esketamine offer rapid-onset relief suitable for acute high-risk cases, while augmentation strategies remain valuable for partial responders. Psychedelic interventions, although still experimental, hold promise as adjunctive options. Furthermore, biomarkers and early response predictors may help guide individualized treatment decisions.

Keywords

treatment resistant depression / ketamine / esketamine / psychedelic / psilocybin / antipsychotic augmentation

References

[1] World Health Organization.Depressive Disorder (Depression) Fact Sheet; WHO: Geneva, Switzerland, 2025.

[2] Papp, M.; Cubała, W.J.; Swiecicki, L.; et al. Perspectives for therapy of treatment-resistant depression. Br J Pharmacol 2022, 179, 4181-4200. https://doi.org/10.1111/bph.15596.

[3] McIntyre, R.S.; Alsuwaidan, M.; Baune, B.T.; et al. Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023, 22, 394-412. https://doi.org/10.1002/wps.21120.

[4] Sforzini, L.; Worrell, C.; Kose, M.; et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol. Psychiatry 2022, 27, 1286-1299. https://doi.org/10.1038/s41380-021-01381-x.

[5] Voineskos, D.; Daskalakis, Z.J.; Blumberger, D.M. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr. Dis. Treat. 2020, 16, 221-234. https://doi.org/10.2147/NDT.S198774.

[6] Aleksandrova, L.R.; Phillips, A.G.; Wang, Y.T. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J. Psychiatry Neurosci. 2017, 42, 222-229. https://doi.org/10.1503/jpn.160175.

[7] d’Andrea, G.; Miuli, A.; Pettorruso, M.; et al. Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI?—Insights from the REAL-ESK study. J. Affect. Disord. 2024, 367, 583-588. https://doi.org/10.1016/j.jad.2024.09.004.

[8] Murrough, J.W.; Iosifescu, D.V.; Chang, L.C.; et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. Am. J. Psychiatry 2013, 170, 1134-1142. https://doi.org/10.1176/appi.ajp.2013.13030392.

[9] Zheng, W.; Li, X.H.; Zhu, X.M.; et al. Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. J. Affect. Disord. 2019, 250, 123-131. https://doi.org/10.1016/j.jad.2019.02.044.

[10] Jawad, M.Y.; Qasim, S.; Ni, M.; et al. The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review. Brain Sci. 2023, 13, 909. https://doi.org/10.3390/brainsci13060909.

[11] Martinotti, G.; Dell’Osso, B.; Di Lorenzo, G.; et al. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disord. 2023, 25, 233-244. https://doi.org/10.1111/bdi.13296.

[12] McIntyre, R.S.; Rodrigues, N.B.; Lipsitz, O.; et al. Validation of the McIntyre and Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment. J. Affect. Disord. 2021, 288, 210-216. https://doi.org/10.1016/j.jad.2021.03.053.

[13] Maina, G.; Adami, M.; Ascione, G.; et al. Nationwide consensus on the clinical management of treatment-resistant depression in Italy: A Delphi panel. Ann. Gen. Psychiatry 2023, 22, 48. https://doi.org/10.1186/s12991-023-00478-7.

[14] Veraart, J.K.; Smith-Apeldoorn, S.Y.; Kutscher, M.; et al. Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression. J. Clin. Psychiatry 2022, 83, 43508. https://doi.org/10.4088/JCP.21m14267.

[15] Martinotti, G.; Vita, A.; Fagiolini, A.; et al. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). J. Affect. Disord. 2022, 319, 646-654. https://doi.org/10.1016/j.jad.2022.09.043.

[16] d’Andrea, G.; Chiappini, S.; McIntyre, R. S.; et al. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults with Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group. Am. J. Geriatr. Psychiatry 2023, 31, 1032-1041. https://doi.org/10.1016/j.jagp.2023.06.016.

[17] Chiappini, S.; d’Andrea, G.; De Filippis, S.; et al. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur. Neuropsychopharmacol. 2023, 74, 15-21. https://doi.org/10.1016/j.euroneuro.2023.04.011.

[18] Drevets, W.C.; Price, J.L.; Furey, M.L. Brain structural and functional abnormalities in mood disorders: Implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213, 93-118. https://doi.org/10.1007/s00429-008-0189-x.

[19] Dwivedi, Y. Brain-derived neurotrophic factor: Role in depression and suicide. Neuropsychiatr. Dis. Treat. 2009, 5, 433. https://doi.org/10.2147/NDT.S5700.

[20] Vrshek-Schallhorn, S.; Doane, L.D.; Mineka, S.; et al. The cortisol awakening response predicts major depression: Predictive stability over a 4-year follow-up and effect of depression history. Psychol. Med. 2013, 43, 483-493. https://doi.org/10.1017/S0033291712001213.

[21] Zunszain, P.A.; Hepgul, N.; Pariante, C.M. Inflammation and Depression. In Behavioral Neurobiology of Depression and Its Treatment; Springer: Berlin/Heidelberg, Germany, 2012; pp. 135-151. https://doi.org/10.1007/7854_2012_211.

[22] Carhart-Harris, R.L.; Goodwin, G.M. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology 2017, 42, 2105-2113. https://doi.org/10.1038/npp.2017.84.

[23] Gukasyan, N.; Nayak, S.M. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcult. Psychiatry 2022, 59, 652-664. https://doi.org/10.1177/1363461520983684.

[24] Goodwin, G.M.; Nowakowska, A.; Atli, M.; et al. Results from a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder. J. Clin. Psychiatry 2025, 86. https://doi.org/10.4088/JCP.24m15449.

[25] Perez, N.; Langlest, F.; Mallet, L.; et al. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. Eur. Neuropsychopharmacol. 2023, 76, 61-76. https://doi.org/10.1016/j.euroneuro.2023.07.011.

[26] Ko, K.; Kopra, E.I.; Cleare, A.J.; et al. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. J. Affect. Disord. 2023, 322, 194-204. https://doi.org/10.1016/j.jad.2022.09.168.

[27] Goodwin, G.M.; Aaronson, S.T.; Alvarez, O.; et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N. Engl. J. Med. 2022, 387, 1637-1648. https://doi.org/10.1056/NEJMoa2206443.

[28] Rucker, J.J.; Jelen, L.A.; Flynn, S.; et al. Psychedelics in the treatment of unipolar mood disorders: A systematic review. J. Psychopharmacol. 2016, 30, 1220-1229. https://doi.org/10.1177/0269881116679368.

[29] Borissova, A.; Rucker, J.J. The development of psilocybin therapy for treatment-resistant depression: An update. BJPsych Bull. 2024, 48, 38-44. https://doi.org/10.1192/bjb.2023.25.

[30] Menon, V.; Ramamurthy, P.; Venu, S.; et al. Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis. Acta Psychiatr. Scand. 2025, 151, 557-571. https://doi.org/10.1111/acps.13778.

[31] Agrawal, M.; Roddy, K.; Jenkins, B.; et al. Long-term benefits of single-dose psilocybin in depressed patients with cancer. Cancer 2025, 131, e35889. https://doi.org/10.1002/cncr.35889.

[32] Agnorelli, C.; Cinti, A.; Barillà, G.; et al. Neurophysiological correlates of ketamine-induced dissociative state in bipolar disorder: Insights from real-world clinical settings. Mol. Psychiatry 2025, 30, 2848-2859. https://doi.org/10.1038/s41380-025-02889-2.

[33] Artin, H.; Bentley, S.; Mehaffey, E.; et al. Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series. EClinicalMedicine 2022, 48, 101439. https://doi.org/10.1016/j.eclinm.2022.101439.

[34] Aust, S.; Gärtner, M.; Basso, L.; et al. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Eur. Neuropsychopharmacol. 2019, 29, 529-538. https://doi.org/10.1016/j.euroneuro.2019.02.005.

[35] Ballard, E.D.; Yarrington, J.S.; Farmer, C.A.; et al. Characterizing the course of suicidal ideation response to ketamine. J. Affect. Disord. 2018, 241, 86-93. https://doi.org/10.1016/j.jad.2018.07.077.

[36] Carhart-Harris, R.L.; Bolstridge, M.; Day, C.M.; et al. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology 2018, 235, 399-408. https://doi.org/10.1007/s00213-017-4771-x.

[37] Chen, M.H.; Kao, C.F.; Tsai, S.J.; et al. Treatment response to low-dose ketamine infusion for treatment-resistant depression: A gene-based genome-wide association study. Genomics 2021, 113, 507-514. https://doi.org/10.1016/j.ygeno.2020.12.030.

[38] Copa, D.; Erritzoe, D.; Giribaldi, B.; et al. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. J. Affect. Disord. 2024, 353, 60-69. https://doi.org/10.1016/j.jad.2024.02.089.

[39] Almeida, R.N.D.; Galvão, A.C.D.M.; da Silva, F.S.; et al. Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation from a Randomized Controlled Trial. Front. Psychol. 2019, 10, 1234. https://doi.org/10.3389/fpsyg.2019.01234.

[40] Dore, J.; Turnipseed, B.; Dwyer, S.; et al. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J. Psychoact. Drugs 2019, 51, 189-198. https://doi.org/10.1080/02791072.2019.1587556.

[41] Guo, W.; Machado-Vieira, R.; Mathew, S.; et al. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl. Psychiatry 2019, 9, 108. https://doi.org/10.1038/s41398-019-0442-5.

[42] Kiraly, D.D.; Horn, S.R.; Van Dam, N.T.; et al. Altered peripheral immune profiles in treatment-resistant depression: Response to ketamine and prediction of treatment outcome. Transl. Psychiatry 2017, 7, e1065. https://doi.org/10.1038/tp.2017.31.

[43] Lipsitz, O.; McIntyre, R.S.; Rodrigues, N.B.; et al. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence. CNS Spectr. 2022, 27, 322-330. https://doi.org/10.1017/S1092852920002102.

[44] Lipsitz, O.; McIntyre, R.S.; Rodrigues, N.B.; et al. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. J. Psychiatr. Res. 2021, 136, 444-451. https://doi.org/10.1016/j.jpsychires.2020.08.002.

[45] Lipsitz, O.; McIntyre, R.S.; Rodrigues, N.B.; et al. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2021, 105, 110126. https://doi.org/10.1016/j.pnpbp.2020.110126.

[46] McIntyre, R.S.; Lipsitz, O.; Lui, L.M.; et al. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine. J. Affect. Disord. 2021, 294, 592-596. https://doi.org/10.1016/j.jad.2021.07.035.

[47] Yoshimura, R.; Kishi, T.; Hori, H.; et al. No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients. Clin. Psychopharmacol. Neurosci. 2012, 10, 49-53. https://doi.org/10.9758/cpn.2012.10.1.49.

[48] Altinay, M.; Karne, H.; Anand, A. Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial. Psychopharmacol. Bull. 2019, 49, 8-16.

[49] Chen, M.H.; Cheng, C.M.; Gueorguieva, R.; et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: A double-blind randomized placebo-control study. Neuropsychopharmacology 2019, 44, 2112-2118. https://doi.org/10.1038/s41386-019-0480-y.

[50] Chen, M.H.; Li, C.T.; Lin, W.C.; et al. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study. J. Affect. Disord. 2018, 225, 709-714. https://doi.org/10.1016/j.jad.2017.09.008.

[51] Li, C.T.; Chen, M.H.; Lin, W.C.; et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study. Hum. Brain Mapp. 2016, 37, 1080-1090. https://doi.org/10.1002/hbm.23085.

[52] Fava, M.; Freeman, M.P.; Flynn, M.; et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol. Psychiatry 2020, 25, 1592-1603. https://doi.org/10.1038/s41380-018-0256-5.

[53] Murrough, J.W.; Collins, K.A.; Fields, J.; et al. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl. Psychiatry 2015, 5, e509. https://doi.org/10.1038/tp.2015.10.

[54] Murrough, J.W.; Burdick, K.E.; Levitch, C.F.; et al. Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. Neuropsychopharmacology 2015, 40, 1084-1090. https://doi.org/10.1038/npp.2014.298.

[55] Murphy, N.; Tamman, A.J.; Lijffijt, M.; et al. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: A randomized control trial. Neuropsychopharmacology 2023, 48, 1586-1593. https://doi.org/10.1038/s41386-023-01586-4.

[56] Galvão-Coelho, N.L.; de Menezes Galvão, A.C.; de Almeida, R.N. et al. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J. Psychopharmacol. 2020, 34, 1125-1133. https://doi.org/10.1177/0269881120936486.

[57] Gebara, M.A.; DiNapoli, E.A.; Kasckow, J.; et al. Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression. Int. J. Geriatr. Psychiatry 2018, 33, e330-e335. https://doi.org/10.1002/gps.4813.

[58] Glue, P.; Loo, C.; Fam, J.; et al. Extended-release ketamine tablets for treatment-resistant depression: A randomized placebo-controlled phase 2 trial. Nat. Med. 2024, 30, 2004-2009. https://doi.org/10.1038/s41591-024-03063-x.

[59] Kadriu, B.; Farmer, C.A.; Yuan, P.; et al. The kynurenine pathway and bipolar disorder: Intersection of the monoaminergic and glutamatergic systems and immune response. Mol. Psychiatry 2021, 26, 4085-4095. https://doi.org/10.1038/s41380-019-0589-8.

[60] Rotroff, D.M.; Corum, D.G.; Motsinger-Reif, A.; et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: New mechanistic insights for rapid acting antidepressants. Transl. Psychiatry 2016, 6, e894. https://doi.org/10.1038/tp.2016.145.

[61] Sousa, G.M.D.; de Oliveira Tavares, V.D.; de Menezes Galvão, A.C.; et al. Moderators of ayahuasca’s biological antidepressant action. Front. Psychiatry 2022, 13, 1033816. https://doi.org/10.3389/fpsyt.2022.1033816.

[62] Saligan, L.N.; Luckenbaugh, D.A.; Slonena, E.E.; et al. An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J. Affect. Disord. 2016, 194, 115-119. https://doi.org/10.1016/j.jad.2016.01.009.

[63] Singh, B.; Port, J.D.; Vande Voort, J.L.; et al. A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. Psychiatry Res. 2021, 301, 113953. https://doi.org/10.1016/j.psychres.2021.113953.

[64] Smagula, S.F.; Wallace, M.L.; Anderson, S.J.; et al. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. J. Psychiatr. Res. 2016, 81, 112-118. https://doi.org/10.1016/j.jpsychires.2016.07.005.

[65] Yonezawa, K.; Uchida, H.; Yatomi, T.; et al. Factors Associated with Antidepressant Effects of Ketamine: A Reanalysis of Double-Blind Randomized Placebo-Controlled Trial of Intravenous Ketamine for Treatment-Resistant Depression. Pharmacopsychiatry 2024, 57, 35-40. https://doi.org/10.1055/a-2179-8884.

[66] Palhano-Fontes, F.; Cavalcanti-Ribeiro, P.; da Costa Gonçalves, K.T.; et al. Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study. J. Affect. Disord. 2025, 369, 155-163. https://doi.org/10.1016/j.jad.2024.09.141.

[67] Rosenblat, J.D.; Meshkat, S.; Doyle, Z.; et al. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med 2024, 5, 190-200. https://doi.org/10.1016/j.medj.2024.01.005.

[68] Reif, A.; Bitter, I.; Buyze, J.; et al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N. Engl. J. Med. 2023, 389, 1298-1309. https://doi.org/10.1056/NEJMoa2304145.

[69] Siegel, J.S.; Palanca, B.J.; Ances, B.M.; et al. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology 2021, 238, 1157-1169. https://doi.org/10.1007/s00213-021-05762-6.

[70] Singh, J.B.; Fedgchin, M.; Daly, E.J.; et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients with Treatment-Resistant Depression. Am. J. Psychiatry 2016, 173, 816-826. https://doi.org/10.1176/appi.ajp.2016.16010037.

[71] Lee, D.Y.; Park, R.W.; Jeon, S.M. Comparison of the efficacy and safety of bupropion versus aripiprazole augmentation in adults with treatment-resistant depression: A nationwide cohort study in South Korea. Eur. Psychiatry 2025, 68, e22. https://doi.org/10.1192/j.eurpsy.2024.1815.

[72] Lähteenvuo, M.; Taipale, H.; Tanskanen, A.; et al. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study. J. Affect. Disord. 2022, 308, 236-242. https://doi.org/10.1016/j.jad.2022.04.010.

[73] Lampela, P.; Tanskanen, A.; Lähteenvuo, M.; et al. Effect of severity of depression on augmentation of antidepressant medication in young adults with depression. Acta Psychiatr. Scand. 2024, 149, 41-51. https://doi.org/10.1111/acps.13633.

[74] Pennybaker, S.; Roach, B.J.; Fryer, S.L.; et al. Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression. Psychopharmacology 2021, 238, 3229-3237. https://doi.org/10.1007/s00213-021-05939-z.

[75] Banwari, G.; Desai, P.; Patidar, P. Ketamine-induced affective switch in a patient with treatment-resistant depression. Indian J. Pharmacol. 2015, 47, 454. https://doi.org/10.4103/0253-7613.161277.

[76] Matteo, M.; Cristian, P.; Laura, M.; et al. The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: A case report. Ann. Gen. Psychiatry 2021, 20, 43. https://doi.org/10.1186/s12991-021-00365-z.

[77] Liester, M.; Wilkenson, R.; Patterson, B.; et al. Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression. Cureus 2024, 16, e57654. https://doi.org/10.7759/cureus.57654.

[78] Bentley, S.; Artin, H.; Mehaffey, E.; et al. Response to intravenous racemic ketamine after switch from intranasal (S)-ketamine on symptoms of treatment-resistant depression and post-traumatic stress disorder in Veterans: A retrospective case series. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2022, 42, 272-279. https://doi.org/10.1002/phar.2664.

[79] Fotiadis, P.; Tsalkitzi, E.; Dimellis, D.; et al. Results of esketamine administration in a Greek population: A case series. Psychiatriki 2024, 35, 243. https://doi.org/10.22365/jpsych.2024.006.

[80] de la, Barquera, J.A.O.-S.; De La Garza García, L.A.; García, S.V.E.; et al. Paradoxical Depressive Response to Intranasal Esketamine in Treatment-Resistant Depression: A Case Series. Am. J. Case Rep. 2024, 26, e945475. https://doi.org/10.12659/AJCR.945475.

[81] Cristancho, P.; Lenard, E.; Lenze, E.J.; et al. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized. Am. J. Geriatr. Psychiatry 2019, 27, 1138-1152. https://doi.org/10.1016/j.jagp.2019.04.005.

[82] Lenze, E.J.; Mulsant, B.H.; Roose, S.P.; et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N. Engl. J. Med. 2023, 388, 1067-1079. https://doi.org/10.1056/NEJMoa2204462.

[83] Papakostas, G.I.; Trivedi, M.H.; Shelton, R.C.; et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol. Psychiatry 2024, 29, 2287-2295. https://doi.org/10.1038/s41380-024-02468-x.

[84] D’Souza, D. C.; Syed, S. A.; Flynn, L. T.; et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 2022, 47, 1854-1862. https://doi.org/10.1038/s41386-022-01344-y.

[85] Kaneriya, S.H.; Robbins-Welty, G.A.; Smagula, S.F.; et al. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression. JAMA Psychiatry 2016, 73, 329. https://doi.org/10.1001/jamapsychiatry.2015.3447.

[86] Lapidos, A.; Lopez-Vives, D.; Sera, C.E.; et al. Patients’ recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. J. Affect. Disord. 2023, 323, 534-539. https://doi.org/10.1016/j.jad.2022.11.090.

[87] Murrough, J.W.; Soleimani, L.; DeWilde, K.E.; et al. Ketamine for rapid reduction of suicidal ideation: A randomized controlled trial. Psychol. Med. 2015, 45, 3571-3580. https://doi.org/10.1017/S0033291715001506.

[88] Nunez, N.A.; Joseph, B.; Pahwa, M.; et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J. Affect. Disord. 2022, 302, 385-400. https://doi.org/10.1016/j.jad.2021.12.134.

[89] Thase, M.E.; Youakim, J.M.; Skuban, A.; et al. Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder. J. Clin. Psychiatry 2015, 76, 1224-1231. https://doi.org/10.4088/JCP.14m09688.

[90] Aronica, R.; Pagani, C.; Favalli, V.; et al. Efficacy of lurasidone in adults with bipolar depression: A systematic review and meta-analysis of its impact on depressive symptoms and disability. J. Affect. Disord. 2025, 381, 100-107. https://doi.org/10.1016/j.jad.2025.03.197.

[91] Tarzian, M.; Soudan, M.; Alhajji, M.; et al. Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy. Cureus 2023, 15, e38071. https://doi.org/10.7759/cureus.38071.

[92] Lin, Y.W.; Chen, Y.C.B.; Hung, K.C.; et al. Efficacy and acceptability of lurasidone for bipolar depression: A systematic review and dose-response meta-analysis. BMJ Ment. Health 2024, 27, e301165. https://doi.org/10.1136/bmjment-2024-301165.

[93] Mishra, B.R.; Mohapatra, D.; Biswas, T.; et al. Comparative efficacy of antidepressant augmentation with amantadine vs. pramipexole in treatment-resistant unipolar depression: A randomised controlled trial. J. Affect. Disord. 2025, 390, 119891. https://doi.org/10.1016/j.jad.2025.119891.

[94] Browning, M.; Cowen, P.J.; Galal, U.; et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: A placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry 2025, 12, 579-589. https://doi.org/10.1016/S2215-0366(25)00194-4.

[95] McAllister-Williams, R.H.; Goudie, N.; Azim, L.; et al. A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study). J. Psychopharmacol. 2025, 39, 106-120. https://doi.org/10.1177/02698811241309622.

[96] Duek, O.; Korem, N.; Li, Y.; et al. Long term structural and functional neural changes following a single infusion of Ketamine in PTSD. Neuropsychopharmacology 2023, 48, 1648-1658. https://doi.org/10.1038/s41386-023-01606-3.

[97] Wilkinson, S.T.; Wright, D.; Fasula, M.K.; et al. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychother. Psychosom. 2017, 86, 162-167. https://doi.org/10.1159/000457960.

[98] Liechti, M.E.; Gasser, P.; Aicher, H.D.; et al. Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program. Neurosci. Appl. 2025, 4, 105525. https://doi.org/10.1016/j.nsa.2025.105525.

[99] Canada, H. Special Access Program for Drugs: Guidance Document for Industry and Practitioners. Available online: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html (accessed on 14 October 2020).

[100] Administration, T.G. Update on MDMA and Psilocybin Access and Safeguards from 1 July 2023. Available online: https://www.tga.gov.au/news/news/update-mdma-and-psilocybin-access-and-safeguards-1-july-2023 (accessed on 3 July 2023).

[101] Medsafe. First Approval for Clinical Use of Psilocybin in Treatment-Resistant Depression. Available online: https://www.medsafe.govt.nz (accessed on 24 July 2025).

[102] Alpha, P. Germany Establishes EU’s First Psilocybin Compassionate Access Program. Available online: https://psychedelicalpha.com/news/germany-establishes-eus-first-psilocybin-compassionate-access-program (accessed on 31 July 2025).

[103] McGuire, A.L.; Cohen, I.G.; Sisti, D.; et al. Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Netw. Open 2024, 7, e2414650. https://doi.org/10.1001/jamanetworkopen.2024.14650.